Impower010 nct02486718
Witryna9 paź 2024 · IMpower010 showed a disease-free survival benefit with atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected … WitrynaIMpower010 (NCT02486718) showed that adjuvant atezo improved disease-free survival (DFS) vs BSC in pts with PD-L1 tumour cell (TC) ≥1% stage II-IIIA NSCLC. While a ctDNA positive (+) status post-surgery (Post-OP ctDNA) conferred poor prognosis, atezo was beneficial vs BSC irrespective of Post-OP ctDNA status (Zhou ESMO-IO 2024). ...
Impower010 nct02486718
Did you know?
Witryna30 maj 2024 · A global Phase III, randomized, open-label trial, IMpower010 (NCT02486718), is being conducted to evaluate the efficacy and safety of atezo vs BSC following adjuvant cisplatin (cis)–based chemotherapy (chemo) in pts with resected stage IB (tumors ≥ 4 cm)-IIIA NSCLC. WitrynaIMpower010 (NCT02486718) showed a statistically significant benefit in primary-endpoint disease-free survival (DFS) with adjuvant atezo vs BSC in resected stage II …
WitrynaPrevious findings from the Phase III IMpower010 ( NCT02486718) trial demonstrated a statistically significant improved disease-free survival (DFS) with atezolizumab compared to best supportive care (BSC) in patients with resected PD-L1 TC ≥1% stage II-IIIA non-small cell lung cancer (NSCLC) following platinum-based chemotherapy. 5 The … Witryna21 cze 2024 · The IMpower010 [NCT02486718] study is the first one to report out at this year’s meeting, and I believe those results will be discussed and potentially integrated into practice. The notion that we could use immune checkpoint inhibitors in early-stage disease to improve overall outcomes is very exciting, and an important step forward in …
Witryna9 paź 2024 · IMpower010 is registered with ClinicalTrials.gov, NCT02486718 (active, not recruiting). Findings Between Oct 7, 2015, and Sept 19, 2024, 1280 patients were enrolled after complete resection. 1269 received adjuvant chemotherapy, of whom 1005 patients were eligible for randomisation to atezolizumab (n=507) or best supportive … Witryna20 wrz 2024 · IMpower010 is a randomised, multicentre, open-label, phase 3 study of atezolizumab versus best supportive care after adjuvant cisplatin-based …
Witryna• In IMpower010 (NCT02486718), adjuvant atezolizumab demonstrated a statistically significant DFS benefit vs BSC in resected NSCLC following platinum-based chemotherapy at the DFS IA 1 – PD-L1 TC ≥1% stage II-IIIA population analysis: DFS HR, 0.66; 95% CI: 0.50, 0.88
Witryna23 sie 2024 · The first pre-specified interim overall survival (OS) analysis of the phase 3 IMpower010 trial displayed a trend towards an OS benefit for patients with stage … graphic designing course in guwahatiWitryna1 lip 2015 · Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung … Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared … chir gneWitryna27 wrz 2024 · Three recent randomized Phase III trials reported significant improvements in disease-free survival with adjuvant immune checkpoint inhibitors or targeted therapy in patients with resectable NSCLC: IMpower010 (atezolizumab vs best supportive care; NCT02486718), KEYNOTE-091 (PEARLS) (pembrolizumab vs placebo; … chirguryWitryna10 wrz 2024 · IMpower010 (NCT02486718) enrolled patients with completely resected, stage IB to IIIA NSCLC with an ECOG performance status of 0 or 1, who had undergone lobectomy/pneumonectomy, and had tumor tissue available for PD-L1 analysis. If patients had stage IB tumors, they had to be 4 cm or greater. chir gsk3Witryna1 wrz 2024 · IMpower010 (NCT02486718) was the first Phase III immunotherapy study to show a statistically significant disease-free survival (DFS) benefit with adjuvant atezolizumab vs best supportive care (BSC) in resected NSCLC following platinum-based chemotherapy (Felip et al. Lancet 2024). chirgwinWitryna9 paź 2024 · IMpower010 is registered with ClinicalTrials.gov, NCT02486718 (active, not recruiting). Findings: Between Oct 7, 2015, and Sept 19, 2024, 1280 patients were … graphic designing company websiteWitryna29 wrz 2024 · Peters highlight the importance of the phase 3 IMpower010 trial (NCT02486718), which examined the use of adjuvant atezolizumab (Tecentriq) in patients with non–small cell lung cancer, as well as the phase 2 FIRSTMAPP trial, which examined the use of sunitinib (Sutent) in pheochromocytoma and paraganglioma … chir greek radio